The AI that designs its
own experiments.
Mokamo closes the hypothesis-to-experiment loop autonomously — generating, testing, and refining its own models on every cycle. Built for drug discovery teams who can't afford to wait.
10×
faster hypothesis iteration
Continuous
model self-improvement
Zero
manual experiment design
The bottleneck
R&D cycles are gated
by human bandwidth.
Researchers spend weeks designing experiments that could be automated.
Hypothesis generation relies on literature review — a process that doesn't scale.
Models are retrained periodically, not continuously — losing signal between cycles.
Each experiment produces data that rarely feeds directly back into the next design.
The Mokamo approach
Close the loop.
Automatically.
Mokamo's self-improving architecture turns each experimental outcome into training signal for the next cycle — without a human in the loop. The system gets measurably better with every experiment it runs.
Platform capabilities
Everything the loop needs.
Mokamo handles the full autonomous experimentation cycle — from hypothesis to model update — so your team focuses on decisions, not design.
Autonomous hypothesis generation
The system formulates and prioritizes hypotheses from prior results, literature signals, and its own internal knowledge — without researcher intervention.
Experiment design engine
Mokamo translates hypotheses into concrete experimental protocols, selecting assay types, conditions, and controls to maximize information gain.
Continuous model improvement
Every experimental outcome is fed directly back into the model. No periodic retraining — the system improves in real time across every cycle.
Branching hypothesis trees
Parallel hypothesis tracks run concurrently, allowing the system to explore multiple mechanistic paths without serial bottlenecks.
Audit trail & reproducibility
Every decision, experiment design, and model update is logged with full provenance — meeting the transparency requirements of pharma R&D.
Domain-agnostic architecture
Built to generalize beyond drug discovery into broader biology, healthcare systems, and critical infrastructure from day one.
Early access
Work with us
before launch.
We're onboarding a small cohort of biotech and pharma R&D teams to shape the platform. If your team runs drug discovery or computational biology research, we want to talk.
Direct access to the founding team
Co-design the features that matter to your workflow
Preferred pricing for early design partners